Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Omnicell (OMCL)

Tipranks - Tipranks - Fri Apr 24, 6:34AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Omnicell (OMCL) and BioCardia (BCDA) with bullish sentiments.

Claim 30% Off TipRanks

Regeneron (REGN)

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron today and set a price target of $960.00. The company’s shares closed last Wednesday at $746.58.

According to TipRanks.com, Buren is a 5-star analyst with an average return of 29.5% and a 57.6% success rate. Buren covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., NewAmsterdam Pharma Company, and Crinetics Pharmaceuticals. ;'>

Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $878.57, which is a 16.9% upside from current levels. In a report issued on April 8, Bernstein also maintained a Buy rating on the stock with a $921.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Omnicell (OMCL)

Wells Fargo analyst Stan Berenshteyn maintained a Buy rating on Omnicell today and set a price target of $55.00. The company’s shares closed last Wednesday at $36.65.

According to TipRanks.com, Berenshteyn has 0 stars on 0-5 stars ranking scale with an average return of -11.8% and a 42.3% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as Omada Health, Inc., GoodRx Holdings, and Health Catalyst. ;'>

Currently, the analyst consensus on Omnicell is a Strong Buy with an average price target of $58.50, implying a 58.0% upside from current levels. In a report issued on April 10, Bank of America Securities also maintained a Buy rating on the stock with a $70.00 price target.

BioCardia (BCDA)

Alliance Global Partners analyst James Molloy reiterated a Buy rating on BioCardia today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.20.

According to TipRanks.com, Molloy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -21.7% and a 24.4% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Neurosense Therapeutics Ltd., and Intensity Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCardia with a $15.50 average price target.

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).